Status:
UNKNOWN
Registry of Bleeding Risk in Real World Chinese Acute Coronary Syndrome Patients-II
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Acute Coronary Syndrome
Percutaneous Coronary Intervention
Eligibility:
All Genders
18-80 years
Brief Summary
The present study was designed to observe the incidence of bleeding events and characteristics of bleeding and exploratively analyse bleeding related biomarkers and gene polymorphisms in ACS patients ...
Detailed Description
Acute coronary syndrome (ACS) is a group of clinical syndromes characterized by rupture or erosion of coronary atherosclerotic plaques secondary to complete or incomplete thrombus formation. With the...
Eligibility Criteria
Inclusion
- age≥18 years, male or female;
- confirmed acute coronary syndrome patients;
- undergo percutaneous coronary intervention (PCI) treatment;
- agree to participate in this clinical study and sign a written consent form.
Exclusion
- ACS admission deemed secondary to other cause such as traffic accidents, trauma, severe upper gastrointestinal bleeding, surgery, or procedure;
- patients who are not intend to attend 1 year of follow-up study or investigators find that patients are not able to comply with the study's requirements;
- pregnant women or lactating women;
- investigators consider patients who were not suitable for participation with other reasons
Key Trial Info
Start Date :
December 14 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2021
Estimated Enrollment :
5500 Patients enrolled
Trial Details
Trial ID
NCT03402711
Start Date
December 14 2017
End Date
April 1 2021
Last Update
January 18 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The General Hospital of PLA
Beijing, China, 100853